Relay Therapeutics, Inc.

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: US75943R1023

USD

15.13

0.04 (0.27%)

Apr 24

NAS

View all stocks in this country

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

ANI Pharmaceuticals, Inc.

Aurinia Pharmaceuticals, Inc.

Tango Therapeutics, Inc.

Deciphera Pharmaceuticals, Inc.

Twist Bioscience Corp.

Geron Corp.

Iovance Biotherapeutics, Inc.

Xencor, Inc.

Relay Therapeutics, Inc.

Arvinas, Inc.

Disc Medicine, Inc.

Why is Relay Therapeutics, Inc. ?

Flat results in Sep 25

NET SALES(9M) At USD 8.36 MM has Grown at -16.5%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 221.07%, its profits have risen by 17.4%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Relay Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Relay Therapeutics, Inc.

374.29%

0.39

71.15%

S&P 500

30.64%

0.62

19.30%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

56.41%

EBIT Growth (5y)

-195.75%

EBIT to Interest (avg)

-283.27

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.98

Sales to Capital Employed (avg)

0.02

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.98

EV to EBIT

-3.72

EV to EBITDA

-3.77

EV to Capital Employed

81.61

EV to Sales

145.73

PEG Ratio

Dividend Yield

ROCE (Latest)

-2192.12%

ROE (Latest)

-48.97%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -248.46 MM

NET PROFIT(HY)

Higher at USD -144.52 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

-2What is not working for the Company

NET SALES(9M)

At USD 8.36 MM has Grown at -16.5%

Here's what is working for Relay Therapeutics, Inc.

Net Profit

Higher at USD -144.52 MM

than preceding 12 month period ended Sep 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Operating Cash Flow

Highest at USD -248.46 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Relay Therapeutics, Inc.

Net Sales

At USD 8.36 MM has Grown at -16.5%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)